AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

The primary objective of this study was to assess the efficacy in terms of overall survival
(OS) of AZD6244 in combination with docetaxel, compared with docetaxel alone, in second-line
patients with KRAS mutation-positive locally advanced or metastatic NSCLC. Amendment 4 of the
CSP altered the primary objective and outcome variable from progression-free survival (PFS)
to OS, and the secondary outcome variable changed from OS to PFS.

The secondary objectives of the study were:

- To further assess the efficacy of AZD6244 in combination with docetaxel, compared with
docetaxel alone, in second-line patients with KRAS mutation-positive locally advanced or
metastatic NSCLC

- To assess the safety and tolerability profile of AZD6244 in combination with docetaxel

- To investigate the use of plasma and serum as a potential source of circulating free
tumour DNA (cfDNA) for the analysis of KRAS mutation status

- To investigate the PK of AZD6244 and N-desmethyl AZD6244 and any other known metabolites
when AZD6244 is administered in combination with docetaxel.

The exploratory objectives of the study were:

- To assess the prevalence, severity and change over time of advanced NSCLC cancer
specific symptoms in patients receiving AZD6244 in combination with docetaxel and
docetaxel alone

- To explore potential biomarkers in residual tumour, plasma and/or serum taken for KRAS
mutational analysis which may influence development of NSCLC (and associated clinical
characteristics) and/or response (optional)

- To investigate the relationship between AZD6244 and/or N-desmethyl AZD6244 and any other
known metabolite plasma concentrations or exposure and clinical outcomes, efficacy, AEs,
and/or safety parameters if deemed appropriate

- To collect and store deoxyribonucleic acid (DNA), derived from a blood sample, for
future exploratory research into genes that may influence response, eg, distribution,
safety, tolerability, and efficacy of AZD6244 and/or agents used in combination and/or
as comparators (optional).

Inclusion Criteria:

- Locally advanced or metastatic non small cell lung cancer (IIIB-IV)

- Failure of first line anti-cancer therapy (either radiological documentation of
disease progression or due to toxicity) in advanced disease or subsequent relapse of
disease following first line therapy

- Tumour sample confirmed as KRAS mutation positive (Note: Sample must be available upon
enrolment to ship to AZ appointed central laboratory, or mutation status confirmed
locally at AstraZeneca agreed local laboratory using agreed methodology, or mutation
status confirmed by an accredited (eg CLIA certified) commercial laboratory (eg
Genzyme or Lab 21).

Exclusion Criteria:

- Received >1 prior anti-cancer therapy for advanced or metastatic non small cell lung
cancer (excluding radiotherapy)

- Prior treatment with a MEK inhibitor or any docetaxel containing regimen (prior
treatment with paclitaxel is acceptable)

- Having received an investigational drug within 30 days of starting treatment, or have
not recovered from side effects of an investigational drug

- Brain metastases or spinal cord compression unless asymptomatic, treated and stable
off steroids and anti-convulsants for at least 1 month